Shravan Kambam, MD
Radiation Oncology · Saddle Brook, NJNPI 1124055272
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 175 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $875, 2.5 times the $344 reported in 2019.
Across 175 payments — averaging $17.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$496
- Incyte Corporation$302
- Bayer$273
- Johnson & Johnson$241
- Merck$204
- GSK$175
- plus $1K from 34 others
What the payments were for
- Food & beverage$3,108100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 26 | $496 |
| Incyte Corporation | 18 | $302 |
| Bayer | 14 | $273 |
| Johnson & Johnson(2 entities) | 14 | $241 |
| Merck | 12 | $204 |
| GSK | 9 | $175 |
| Novartis | 10 | $168 |
| Lilly USA, LLC | 7 | $125 |
| Amgen | 6 | $105 |
| Emmaus Medical, Inc. | 4 | $96 |
| Daiichi Sankyo Inc. | 6 | $95 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $87 |
| Taiho Oncology, Inc. | 4 | $74 |
| Eisai Inc. | 4 | $70 |
| Stemline Therapeutics Inc. | 4 | $67 |
| Seagen Inc. | 2 | $35 |
| Apellis Pharmaceuticals, Inc. | 2 | $32 |
| Bio Products Laboratory USA, Inc. | 2 | $32 |
| CSL Behring | 2 | $31 |
| Octapharma USA, Inc. | 2 | $31 |
| Boehringer Ingelheim | 2 | $30 |
| Bristol Myers Squibb | 2 | $28 |
| Sanofi | 1 | $23 |
| Beone Medicines USA, Inc. | 1 | $22 |
| Pfizer | 1 | $20 |
| Pharmacosmos Therapeutics Inc. | 1 | $20 |
| Geron Corporation | 1 | $19 |
| Agios Pharmaceuticals, Inc. | 1 | $19 |
| AVEO Pharmaceuticals, Inc. | 1 | $18 |
| Pharmaessentia USA Corporation | 1 | $18 |
| Macrogenics, Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $18 |
| Deciphera Pharmaceuticals Inc. | 1 | $17 |
| Array Biopharma Inc | 1 | $16 |
| Mirati Therapeutics, Inc. | 1 | $15 |
| Tesaro, Inc. | 1 | $15 |
| Rigel Pharmaceuticals, Inc. | 1 | $14 |
| Biomarin Pharmaceutical Inc. | 1 | $14 |
| Sobi, Inc | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
How this compares
$3,108 in reported general payments places this provider in the 80th percentile of 132 radiation oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other radiation oncology in Saddle Brook
- Michael GreenbergCherry Hill$335K
- Glen GejermanHackensack$180K
- Marc RudoltzWest Orange$166K
- Salma JabbourNew Brunswick$163K
- Edward SoffenMonroe Twp$50K
- Adnan DanishWayne$45K
- Timothy ChenPennington$43K
- Brett LewisHackensack$23K
- Sang SimLong Branch$16K
- Thomas KoleMiddletown$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.